- Home
- IPDN vs LIXT Comparison
IPDN vs LIXT Comparison
Compare IPDN & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPDN
- LIXT
- Stock Information
- Founded
- IPDN 2003
- LIXT 2005
- Country
- IPDN United States
- LIXT United States
- Employees
- IPDN N/A
- LIXT N/A
- Industry
- IPDN EDP Services
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- IPDN Technology
- LIXT Health Care
- Exchange
- IPDN Nasdaq
- LIXT Nasdaq
- Market Cap
- IPDN 4.3M
- LIXT 4.1M
- IPO Year
- IPDN 2013
- LIXT N/A
- Fundamental
- Price
- IPDN $1.97
- LIXT $1.19
- Analyst Decision
- IPDN
- LIXT
- Analyst Count
- IPDN 0
- LIXT 0
- Target Price
- IPDN N/A
- LIXT N/A
- AVG Volume (30 Days)
- IPDN 36.7K
- LIXT 31.7K
- Earning Date
- IPDN 05-14-2025
- LIXT 03-24-2025
- Dividend Yield
- IPDN N/A
- LIXT N/A
- EPS Growth
- IPDN N/A
- LIXT N/A
- EPS
- IPDN N/A
- LIXT N/A
- Revenue
- IPDN $6,730,605.00
- LIXT N/A
- Revenue This Year
- IPDN N/A
- LIXT N/A
- Revenue Next Year
- IPDN N/A
- LIXT N/A
- P/E Ratio
- IPDN N/A
- LIXT N/A
- Revenue Growth
- IPDN N/A
- LIXT N/A
- 52 Week Low
- IPDN $1.80
- LIXT $1.02
- 52 Week High
- IPDN $18.90
- LIXT $3.80
- Technical
- Relative Strength Index (RSI)
- IPDN 40.12
- LIXT 41.29
- Support Level
- IPDN $2.40
- LIXT $1.18
- Resistance Level
- IPDN $2.59
- LIXT $1.31
- Average True Range (ATR)
- IPDN 0.21
- LIXT 0.10
- MACD
- IPDN 0.05
- LIXT 0.03
- Stochastic Oscillator
- IPDN 23.33
- LIXT 43.24
About IPDN Professional Diversity Network Inc.
Professional Diversity Network Inc is engaged in providing access to networking, training, educational and employment services to its registered users. It has three operating segments: the Professional Diversity Network (PDN) segment, which includes online professional networking communities with career resources for diverse cultural groups and employers looking to hire members; and the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization, the RemoteMore segment. The company generates majority of its revenue from PDN Segment.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.